Egyptian International Pharmaceutical Industries Company

CASE:PHAR Stock Report

Market Cap: ج.م14.4b

Egyptian International Pharmaceutical Industries Past Earnings Performance

Past criteria checks 4/6

Egyptian International Pharmaceutical Industries has been growing earnings at an average annual rate of 23.3%, while the Pharmaceuticals industry saw earnings growing at 22.2% annually. Revenues have been growing at an average rate of 26.4% per year. Egyptian International Pharmaceutical Industries's return on equity is 25.1%, and it has net margins of 14.5%.

Key information

23.33%

Earnings growth rate

10.64%

EPS growth rate

Pharmaceuticals Industry Growth9.80%
Revenue growth rate26.44%
Return on equity25.06%
Net Margin14.54%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Egyptian International Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CASE:PHAR Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 269,6741,4071,64272
31 Dec 259,4411,4421,62471
30 Sep 259,2961,2571,50576
30 Jun 258,8191,1371,49168
31 Mar 258,3878111,40165
31 Dec 247,5911,0961,45770
30 Sep 247,0031,1631,02161
30 Jun 246,3441,09396059
31 Mar 245,7421,23790453
31 Dec 235,23282282743
30 Sep 234,94986980544
30 Jun 234,49184877843
31 Mar 234,02065874342
31 Dec 223,95564371844
30 Sep 223,64858166841
30 Jun 223,59555666243
31 Mar 223,55149461941
31 Dec 213,40948857935
30 Sep 213,17147257332
30 Jun 212,97846154335
31 Mar 212,90146553927
31 Dec 202,88648754821
30 Sep 202,96948853515
30 Jun 203,1135347520
31 Mar 203,2666416520
31 Dec 193,4116715400
30 Sep 193,2947314330
30 Jun 193,126711970
31 Mar 192,999735940
31 Dec 182,816701890
30 Sep 182,784611810
30 Jun 182,767688810
31 Mar 182,654714790
31 Dec 172,527688740
30 Sep 172,372671690
30 Jun 172,210642710
31 Mar 172,079522700
31 Dec 161,969487740
30 Sep 161,873466860
30 Jun 161,793448770
31 Mar 161,745427740
31 Dec 151,697393640
30 Sep 151,682403650
30 Jun 151,646340710

Quality Earnings: PHAR has a high level of non-cash earnings.

Growing Profit Margin: PHAR's current net profit margins (14.5%) are higher than last year (9.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PHAR's earnings have grown significantly by 23.3% per year over the past 5 years.

Accelerating Growth: PHAR's earnings growth over the past year (73.5%) exceeds its 5-year average (23.3% per year).

Earnings vs Industry: PHAR earnings growth over the past year (73.5%) exceeded the Pharmaceuticals industry 25.2%.

Return on Equity

High ROE: Whilst PHAR's Return on Equity (25.06%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 07:01
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Egyptian International Pharmaceutical Industries Company is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michel SaidCI Capital Research
Ahmed MoatazEFG-Hermes Research
NematAllah ChoucriHC Brokerage